COPD Management with Trelegy Ellipta

Indications and Treatment Algorithm

The American Thoracic Society recommends Trelegy Ellipta as a triple therapy for patients with moderate to severe COPD who have persistent symptoms and high exacerbation risk, particularly those with FEV₁ <60% predicted who are not adequately controlled on dual therapy 1, 2
For moderate to severe COPD with moderate symptoms (CAT ≥10, mMRC ≥2) and FEV₁ <80% predicted, LAMA/LABA dual therapy is recommended as initial maintenance therapy, according to the American College of Chest Physicians 1, 3
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy with LAMA/LABA/ICS for COPD Group D patients, with consideration for roflumilast if FEV₁ <50% predicted and patient has chronic bronchitis 4

For patients with features of asthma-COPD overlap, ICS-containing regimens are particularly important, as stated by the American College of Allergy, Asthma, and Immunology 2
Blood eosinophil counts ≥150 cells/mm³ may predict better response to ICS-containing regimens, according to the European Respiratory Society 2
The American Heart Association recommends considering cardiovascular comorbidities when using LABA-containing medications 2

Failing to reassess therapy effectiveness after initiating or switching medications, as advised by the American College of Physicians 2
Not considering comorbidities when selecting therapy, according to the Mayo Clinic 2, 4
Using triple therapy in patients who may be adequately controlled on monotherapy or dual therapy, as cautioned by the Annals of Internal Medicine 3, 4
Not providing proper inhaler technique education, which is crucial for effective medication delivery, as emphasized by the Mayo Clinic 4

The American Thoracic Society recommends the use of triple therapy, including an inhaled corticosteroid (ICS) like fluticasone furoate, a long-acting muscarinic antagonist (LAMA) like umeclidinium, and a long-acting beta2-adrenergic agonist (LABA) like vilanterol, for patients with moderate to severe COPD who are not adequately controlled on dual therapy 5
Fluticasone furoate, an ICS, reduces inflammation and airway hyperresponsiveness, while umeclidinium, a LAMA, induces bronchodilation by inhibiting muscarinic receptors, and vilanterol, a LABA, provides sustained bronchodilation by stimulating beta2-adrenergic receptors, resulting in improved lung function and symptom control in patients with COPD and asthma 5